Compare Cytokinetics Inc (CYTK) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Otis Worldwide Corp — how do they compare? Cytokinetics Inc trades at $81.44 (market cap $11.12B), while Otis Worldwide Corp trades at $72.65 (market cap $27.84B). The key difference: Otis Worldwide Corp is far larger — about 2.5× Cytokinetics Inc's market cap, and Otis Worldwide Corp pays a 2.34% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | OTIS | |
|---|---|---|
Market Cap | $11.12B | $27.84B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $101.07 |
52-Week Low | $33.23 | $69.34 |
Enterprise Value | $11.59B | $35.23B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Otis Worldwide trades at $73.42, up 0.45% today, with a bullish technical signal from moving averages but mixed quarterly earnings. The company maintains stable revenue near $14.4B (2025) and a net margin of 10.11%, supported by service growth and modernization initiatives like recent upgrades at Christ the Redeemer in Brazil. Cash flow from operations remains strong at $1.6B, though net cash flow turned negative in 2025 due to financing activities.
The stock offers 24% upside to the consensus price target of $91.00, with analysts divided (38% Buy, 54% Hold). Risks include debt levels (75.54% debt-to-asset ratio) and margin pressure from tariffs, but dividend growth (5% increase to $0.44) and buybacks provide shareholder value. Near-term performance hinges on Q2 2026 earnings due July 22, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
